Navigation Links
Clinical Study Shows Sustamine(TM) L-Alanyl-L-Glutamine Increases Performance in Endurance, Exercise and Activity

NEW YORK, Feb. 11 /PRNewswire/ -- A clinical study by Dr. Jay Hoffman, PhD, professor and chair of the Department of Health and Exercise Science at the College of New Jersey, has shown Sustamine™ L-Alanyl-L-Glutamine, increases performance in endurance exercise and activity. The study was published on February 3, 2010, in the Journal of the International Society of Sports Nutrition (JISSN), a peer-reviewed journal covering various aspects of sports nutrition, supplementation, exercise metabolism, and/or scientific policies related to sports nutrition.


The data published in the Journal of ISSN shows:

  • Significant performance reduction occurred when exercising to exhaustion in subjects' hypohydrated to 2.5% of body mass. 
  • When subjects ingested the Sustamine™ supplement during the rehydration period the magnitude of performance reduction was significantly less compared to the dehydrated condition. 
  • Water alone did not appear to significantly off-set the performance reduction.

The study showed the efficacy of Sustamine L-Alanyl-L-Glutamine ingestion during Hydration Stress under intense exercise. The clinical study covered the ability of Sustamine L-Alanyl-L-Glutamine to enhance fluid regulation in healthy, active individuals in relation to both endurance and high intensity exercise. Further discussion focuses on the potential ergogenic benefit that Sustamine™ has under these exercise and hydration stresses.  The role that this dipeptide has on the inflammatory, immune and recovery responses to these stresses was also examined.

Sustamine™ is the only GRAS (Generally Recognized As Safe) form of L-Alanyl-L-Glutamine for a variety of food, beverage and healthcare applications. It appears to increase electrolyte and fluid uptake across the intestines by increasing ion transport through an enhanced signaling pathway within the intestinal mucosal cells. Its implications for exercise are enhancement of fluid regulation during prolonged exercise in the heat, maintaining or enhancing performance during a hydration/heat stress, and enhancing recovery from exercise by modulating immune, inflammatory and oxidative stress responses to physical activity. 

Sustamine™, manufactured by Kyowa Hakko Bio Co. Ltd., is considered a "high-tech" amino acid dipeptide that promotes muscle rehydration, recovery and can be used as a source for energy refueling. Produced by a novel and cost effective patented fermentation technology, Sustamine™ L-Alanyl-L-Glutamine is available in powder form and is water-soluble into a clear solution. It is also odorless and tasteless.

Additional Sustamine™ highlights include:

  1. Patent pending for improved endurance performance
  2. Only stable form of glutamine for solutions or ready to drink beverages
  3. Stable in beverages with broad pH ranges
  4. Stable in beverages for over one year at room temperature

Dr. Hoffman's November 2009 SupplySide West seminar, Efficacy of Sustamine™ L-Alanyl-L-Glutamine Ingestion During Hydration Stress Under Intense Exercise is available for viewing at

Kyowa Hakko Bio is an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Hydrafend™ Hyaluronic Acid, Lumistor® L-Hydroxyproline, Setria® Glutathione, Kyowa CoQ10™ as well as Sustamine™ L-Alanyl-L-Glutamine.

Kyowa offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.

Additional information on Sustamine™ L-Alanyl-L-Glutamine can be found online at or contact Kyowa at or


SOURCE Kyowa Hakko



SOURCE Kyowa Hakko
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):